AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06442709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Asprin
Description: Tocilizumab alone, Asprin alone, Tocilizumab combined with Asprin. Tocilizumab, an IL6R inhibitor, injected once a month at a dose of 4mg/kg in advanced NPC patients.~Asprin，an anticoagulant, taken orally once daily at a dose of 100mg in advanced NPC patients.
Study NCT06442709 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo replaces tocilizumab and asprin in advanced NPC patients.
Study NCT06169748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real UHCDS a-tDCS
Description: Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
Study NCT06169748 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham UHCDS a-tDCS
Description: Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
Study NCT06169748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
Study NCT06169748 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
Study NCT06169748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
Study NCT05967351 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: No study drug will be administered as part of this study. Eligible participants who received treatment with delandistrogene moxeparvovec during a previous clinical study will be included.
Study NCT04632966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: PTP-001
Description: allogeneic placental tissue particulate
Study NCT06283888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP2C19 Genotype Guided DAPT
Description: Patients with \*2 or \*3 carrier will be received ticagrelor 60mg or 45mg bid (if \<50 kg, ≥75 years) + aspirin 100 mg qd; Patients with \*2 or \*3 non-carrier will be received clopidogrel 75mg qd + aspirin 100 mg qd
Study NCT06283888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional DAPT
Description: Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd
Study NCT06561581 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acuity
Description: Enhancement to Motivity product for clinical decision support
Study NCT06561581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acuity
Description: Enhancement to Motivity product for clinical decision support
Study NCT04759989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Actual Body Weight Dosing
Description: 30cc/kg initial bolus calculated using Actual Body Weight
Study NCT04759989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjusted Body Weight Dosing
Description: 30cc/kg initial bolus calculated using Adjusted Body Weight
Study NCT04759989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ideal Body Weight Dosing
Description: 30cc/kg initial bolus calculated using Ideal Body Weight
Study NCT05945472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive reinforcement method
Description: A 30-minute talk based on mindfulness, positive thinking and teaching for the application of the cosmetic through positive messages (Ayuna method). Adapts the teachings of mindfulness to the field of beauty and stimulates the skin-brain connection through self-care. By applying cosmetics through intentional massages, with this technique is stimulated the brain in a positive positively in the general wellbeing.~The cosmetic is applied with a massage aimed at loving oneself, a ceremony for the skin and an invitation to enjoy the moment; positive messages are included during the application. In addition to favoring the penetration of the products, these maneuvers help to disconnect and achieve, in the long term, a healthier appearance. The technique consists of slow, intentional movements to create an ideal space to become aware of the present moment and draw a love story with oneself.
Study NCT05945472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard method
Description: A 30-minute talk based on how to administer it according to the guidelines of general cosmetology, related to the use and application of the cream, following conventional techniques of the cosmetic industry, which focus on the application of the product in the areas of wrinkles or with more treatment needs: anti-aging anti-stain anti-sagging anti-sagging product, anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging product. rejuvenating results to try to reduce the skin years, reduce wrinkles, loss of firmness, flaccidity and spots.
Study NCT05089903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bulk Order
Description: A mammogram order will be placed using bulk order technology in the EHR in advance of outreach for all patients.
Study NCT05089903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting
Description: In addition to outreach, patients will receive text messaging with information regarding the importance of screening, how to schedule a mammogram, and locations available for mammography.
Study NCT05089903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Endorsement
Description: Outreach informing patients that they are overdue for a mammogram will be signed by the patient's primary care provider.
Study NCT05089903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Bulk Order
Description: The outreach will ask patients to contact their PCP's office in order to have a mammogram order placed on their behalf.
Study NCT05089903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Endorsement
Description: Patient's will receive outreach from the practice informing them that they are overdue for a mammogram.
Study NCT06203080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ancetate gel
Description: An acetic acid thermoreversible gel produced by Shanghai Jinxiang Latex Products Co. will be utilized for the intervention. Each product weighs 4.85 g and contains 54.45 mg of poloxamer 407-acetic acid. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
Study NCT06203080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nonoxinol gel
Description: The nonoxinol gel produced by China Pharmaceutical University Pharmacy Co., Ltd will be utilized for the intervention. Each product weighs 5 g and contains 50 mg of N-9. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
Study NCT06484543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maslinic Acid
Description: Consumption of Maslinic Acid for 12 weeks
Study NCT06484543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consumption of Placebo for 12 weeks
Study NCT04834388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra treatment is started within 8 hours of symptom onset
Study NCT06547996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tES-tDCS group
Description: 2mA/20mins/session
Study NCT06547996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tES-tACS group
Description: 2mA/40Hz/20mins/session
Study NCT06547996 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tES-sham group
Description: 0mA/20mins/session
Study NCT05132582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 300mg given by mouth (orally) twice daily
Study NCT05132582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days
Study NCT05132582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days
Study NCT05132582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: 420mg given by IV every 21 days
Study NCT05132582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 420mg given by IV every 21 days
Study NCT05132582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination product: Trastuzumab + Pertuzumab
Description: 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.
Study NCT05132582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination product: Trastuzumab + Pertuzumab
Description: 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.
Study NCT05132582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given orally twice daily
Study NCT04803708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TP-102
Description: One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10\^9 plaque forming units per milliliter (PFU/mL).
Study NCT05192031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation support
Description: Training healthcare professionals to deliver smoking cessation support as part of hospital-based lung cancer workup.
Study NCT06107062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol - fsCBD
Description: Full-spectrum (i.e., fsCBD, 7.8mg THC (3.4mg BID)), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used.
Study NCT06107062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study NCT06107062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol - bsCBD
Description: Broad-spectrum (i.e., bsCBD, 0% THC), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used
Study NCT06399705 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary artery bypass grafting
Description: Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.
Study NCT06399705 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
Study NCT05258058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory and Adaptation Training-Geriatrics
Description: MAAT-G is a cognitive behavioral therapy-based intervention comprised of 10 workshop sessions as well as a participant workbook. The workshop sessions are delivered one on one by a health professional via videoconferencing technology.
Study NCT05684523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valerian-Hop Extract
Description: herbal drug
Study NCT05883137 — intervention group
Intervention type: DEVICE
Intervention: Optiflow Switch
Description: High flow nasal oxygen with the Optiflow Switch device
Study NCT05764798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental group: Shugan Jieyu Capsule combined with zolpidem
Description: Shugan Jieyu capsule and zolpidem orally for 8 consecutive weeks
Study NCT05764798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group: Placebo combined with zolpidem
Description: Placebo and zolpidem orally for 8 consecutive weeks
Study NCT06554613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 5mg qd (once daily), q3w(every 3 weeks), oral therapy，Administered continuously for 6-8 weeks.
Study NCT06554613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.
Study NCT06554613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.
Study NCT06017063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: The intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.
Study NCT06027320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Education
Description: Subjects will receive an Alzheimer's risk assessment, memory testing, and brain health education, in addition to text message communication.
Study NCT06027320 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Alzheimer Disease Education
Description: Subjects will receive an Alzheimer's risk assessment, memory testing, and general education about Alzheimer's disease, in addition to text message communication.
Study NCT06041529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg
Description: PO, Once daily(QD), 8 weeks and 26 weeks if applicable
Study NCT06041529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
Description: PO, Once daily(QD), 8 weeks and 26 weeks if applicable
Study NCT05684523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05547555 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: embryo selection
Description: The basis of embryo selection for transfer: invasive PGT-A or after non-invasive PGT-A
Study NCT06179212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise Tests
Description: Patients will complete 4 different cardiopulmonary exercise tests in random order.
Study NCT04550546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin
Description: 600,000 U/mL of nystatin in a rinse suspension
Study NCT04936672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brisk walking and Tai Chi Chuan
Description: This study includes four groups, the three experimental groups are brisk walking group, Tai chi chuan group, brisk walking combined with Tai chi chuan group, and control group. Among the three experimental groups and exercise time, exercise intensity and exercise frequency are the same over time.
Study NCT04579068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention of Problematic Alcohol Use
Description: Provide/enhance knowledge, screening and detection, modify attitudes, motivate and provide skills and resources to reduce alcohol related risk and consumption.
Study NCT05791825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cultivating Healthy Intentional Mindful Educators
Description: The 8-week, manualized, CHIME intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Each CHIME session focuses on a specific mindfulness technique, such as mindful breathing, mindful listening and bringing attention to current states and surroundings to support optimal responsiveness, emotion regulation, and compassion. Social emotional learning is promoted by focusing on five broad competencies: self-awareness, social awareness, responsible decision-making, self-management, and relationship skills and these competencies are practiced and developed through small group discussions, storytelling, journal reflections, modeling, and guided awareness (e.g., meditations), and implementation activities (e.g., gratitude necklace).
Study NCT05329467 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Validation of Faces Thermomether Scale
Description: Participants are introduced to all three painscales and are asked to rate their pain with each and one of them according to instructions for each scale
Study NCT05585437 — intervention group
Intervention type: PROCEDURE
Intervention: gastric cancer specialist training program
Description: The gastric cancer specialist training program includes technical training and non-technical training. The technical training includes 1. The whole process of laparoscopic gastric cancer surgery technical teaching 2. Operation practice 3. Operation video review, non-technical training includes 1. Difficult case discussion 2. Specialists Session 3. Lymph node sorting training.
Study NCT05382676 — intervention group
Intervention type: DEVICE
Intervention: Eyeswift Pro
Description: assessment of visual function parameters
Study NCT04818450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 100-300 mg is given to the intervention group
Study NCT04151563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on Specified days
Study NCT04151563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified dose on Specified days
Study NCT04151563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Specified dose on Specified days
Study NCT04151563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Specified dose on Specified days
Study NCT04151563 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Specified dose on Specified days
Study NCT04151563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: Specified dose on Specified days
Study NCT04151563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lucitanib
Description: Specified dose on Specified days
Study NCT05589636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bergamot Juice
Description: Bergamot Juice (35% in water)
Study NCT04841798 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: [11C]SL25.1188 PET radiotracer
Description: Monoamine oxidase B (MAO-B) occupancy before and after medication treatment using \[11C\]SL25.1188 PET
Study NCT05027750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Application of The Theory of Planned Behaviour For Weight Control
Description: The training to be imparted to the participants was applied online in groups of 5-6 people via the Google Meet program. Obesity training consisting of a total of five sessions. Each session lasted for approximately 30 minutes. After the training given to intervention group, the women will be followed-up for 6 months. The women in the intervention group will be given counseling service by the researchers, and their status will be evaluated every month.
Study NCT06427681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH006 for injection
Description: According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
Study NCT06427681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant for injection+Palonosetron hydrochloride injection
Description: According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
Study NCT06480474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: The internet-based self-help program used in this study, Deprexis, contains 10 modules ( based on different psychotherapeutic approaches, consistent with a cognitive-behavioral perspective) and accessible at any time via regular internet browsers on laptops, computers, tablets, or smartphones through a secure website. Participants can repeat all modules as often as they wish after completing the full sequence once.